KRAS and colorectal carcinoma: Since the previous clinical trial for CRC showed additional benefit from bevacizumab to chemotherapy regimen (73), bevacizumab is combined with KRAS G12C inhibitors in early-phase clinical trials (NCT04185883, NCT04449874).